Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Sarcoma, Kaposi 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Head and Neck Neoplasms 1HIV Infections 1Carcinoma, Renal Cell 1Carcinoma, Adenoid Cystic 1AIDS-related Kaposi sarcoma 1AIDS-Related Opportunistic Infections 1

Interventions

Cyclophosphamide 59Dexamethasone 56Melphalan 48Peripheral Blood Stem Cell Transplantation 37Busulfan 34Bortezomib 32fludarabine phosphate 29Lenalidomide 27Filgrastim 27Tacrolimus 24Antilymphocyte Serum 24Thalidomide 22Mycophenolic Acid 22Radiotherapy 21Methotrexate 15Cyclosporine 15Etoposide 14sargramostim 13Granulocyte Colony-Stimulating Factor 11Whole-Body Irradiation 10Methylprednisolone 10Interferon-alpha 10fludarabine 9daratumumab 9Carmustine 9carfilzomib 7Rituximab 7Prednisone 7Cytarabine 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Plasma Cell × Nelfinavir × Clear all
NCT02188537 2019-06-26

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Swiss Cancer Institute

Phase 2 Completed
34 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡